Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation

Genetics Clinical Trial

Official title: Nonrandomized Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation

Status Completed

Clinical Trial Summary

Background:

• PIK3CA-related overgrowth spectrum (PROS) is caused by changes in the PIK3CA gene. This gene makes a protein that communicates with other proteins in the body to cause cells to grow. Alterations in PIK3CA change the chemical signals in the body and cause overgrowth in fatty, vascular and other tissues. Sirolimus is a drug that reduces the signals sent by one of the proteins in this chemical signaling pathway. Researchers want to learn whether the drug sirolimus can reduce or stabilize some of the overgrowth that patients with PROS experience.

Objectives:

• To measure how the overgrowth of patients with PROS changes over time and whether taking a drug called sirolimus can reduce or stabilize a person s overgrowth.

Eligibility:

• People ages 3 to 65 years old with a confirmed mutation or alteration of the PIK3CA gene in the person s affected tissues (a somatic mutation).

Design:

• Participants will be screened with medical history and genetic counseling.

• First 6 months: Participants will have their overgrowth monitored.

• Next 6 months: Participants will take sirolimus once or twice a day.

• Participants will have to visit the clinic several times, and stay in the area for 4 to 5 days each time.

• Participants will have a one month-long visit to the clinic.

• During clinic visits, participants will have:

• Blood and urine tests.

• Photographs of their physical features.

• Scans, including an MRI and DEXA, and possibly x-rays and CT scans.

• For the MRI and CT scans, participants will lie in a machine that takes pictures of their body.

• The DEXA involves a small amount of radiation.

• They may have:

• Non-invasive heart function tests.

• Lung function tests.

• Participants will have several blood and urine tests between visits.

• Participants will complete surveys and keep a diary of their treatment and side effects.

• Participants may visit other health specialists or undergo other tests based on side effects.

• One month after stopping the study drug, participants will have 1 clinic visit.

Clinical Trial Description

The primary study objective is to determine the likely size of sirolimus treatment effect. The patient population will include male and female subjects, aged greater than or equal to 3 years and less than or equal to 65 years of age with segmental overgrowth identified to have clinical and molecular findings of somatic PIK3CA gene mutation. The planned study size will be ten patients seen at the NIHCC. An additional 20 patients will be contributed by two other centers, who will be responsible for the conduct of the proposed research at their site, but the study procedures and dosing schedule will be identical to enable pooling of results for statistical analyses. The study design will be a nonrandomized, open label, phase II pilot study of sirolimus treatment. As patients have highly variable clinical presentations, and there are no established evidence-based methodologies for measuring serial changes in growth, the aim of this pilot study is to establish the optimal methodology for evaluating changes in growth to inform the design of a future randomized controlled trial, in addition to determining treatment effect size, and evaluating safety and toxicity of low dose sirolimus. Overall desired outcome will be reduced size of affected body part, and measures will include: reduction in affected tissue (fibroadipose or bone) size by clinical exam measurement and by radiological studies (MRI area measurements and/or DXA study measurements of fat). ;

Related Conditions & MeSH terms

• Genetics
• Growth Disorder
• Growth Disorders
• PIK3CA-Related Overgrowth Spectrum (PROS)

• NCT number: NCT02428296
• Study type: Interventional
• Source: National Institutes of Health Clinical Center (CC)
• Status: Completed
• Phase: Phase 2
• Start date: April 23, 2015
• Completion date: February 14, 2018